decompensated liver cirrhosis
Conditions
Interventions
umbilical cord mesenchymal stem cells treatment group:umbilical cord mesenchymal stem cells and given conventional drug treatment
control group :given conventional drug treatment.
Sponsors
The First Affiliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Clinically diagnosed as a patient with decompensated liver cirrhosis; 2.Aged 18 to 65 years; 3.The HBV/HCV viral load has been lower than the detection level for more than 6 months. Child-Pugh B or C or MELD score > 10; 4.For other causes of liver cirrhosis,the liver function is decompensated; 5.After standard medical treatment for at least 6 months, the liver function continued to deteriorate with the at least one episode of the following complications:massive ascites, spontaneous bacterial peritonitis, variceal bleeding and hepatic encephalopathy; 6.Need intermittent albumin infusion and diuretic treatment; 7.At the time of stem cell treatment, the albumin should be 30% (prothrombin time = 7 points; 8.No active variceall bleeding in the past 4 weeks, and the the rebleeding risk is not very high before treatment; 9.Not able to received orthotopic liver transplantation; 10.Agree to sign the informed consent.
Exclusion criteria
Exclusion criteria: 1.Malignant tumors of the liver or other organs or any history of malignant tumors; 2.Complicated with variceal bleeding, spontaneous peritonitis, hepatic encephalopathy, liver and kidney syndrome, and acute infection at the time of treatment; 3.Patients with severe heart, lung, kidney or blood system diseases; 4.Pregnant or breastfeeding women; 5.Allergic constitution; 6.People who have a history of alcohol or drug abuse and have not compleately quited; 7.Participated in other clinical trials within 3 months; 8.Any reasons that the investigators believe that patients should not participate in other situations in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The 2-year overall survival rate;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver function;Model for end-stage liver disease;Child-pugh score;Karnofsky functional status score improvement; | — |
Countries
China
Contacts
Public ContactZhu Yueyong
The First Affiliated Hospital of Fujian Medical University
Outcome results
None listed